Protalix Biotherapeutics (PLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2014 | 09-2014 | 06-2014 | 03-2014 | 12-2013 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -29,943 | -21,474 | -13,464 | -7,345 | -27,790 |
| Depreciation Amortization | 3,584 | 2,750 | 1,848 | 937 | 3,539 |
| Accounts receivable | -1,006 | -578 | -397 | -744 | N/A |
| Accounts payable and accrued liabilities | N/A | -1,736 | 180 | -450 | N/A |
| Other Working Capital | -2,226 | -7,384 | -3,789 | -2,666 | 3,049 |
| Other Operating Activity | 310 | 4,015 | 763 | 1,928 | -9,451 |
| Operating Cash Flow | $-29,281 | $-24,407 | $-14,859 | $-8,340 | $-30,653 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -90 | -93 | -93 | -57 | -42 |
| PPE Investments | -774 | -617 | -371 | -263 | -1,890 |
| Other Investing Activity | -137 | -122 | -101 | -50 | -170 |
| Investing Cash Flow | $-1,001 | $-832 | $-565 | $-370 | $-2,102 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 66,780 |
| Common Stock Issued | 46 | 43 | 31 | 31 | 112 |
| Financing Cash Flow | $46 | $43 | $31 | $31 | $66,892 |
| Exchange Rate Effect | -1,395 | -885 | 139 | -29 | 226 |
| Beginning Cash Position | 86,398 | 86,398 | 86,398 | 86,398 | 52,035 |
| End Cash Position | 54,767 | 60,317 | 71,144 | 77,690 | 86,398 |
| Net Cash Flow | $-31,631 | $-26,081 | $-15,254 | $-8,708 | $34,363 |
| Free Cash Flow | |||||
| Operating Cash Flow | -29,281 | -24,407 | -14,859 | -8,340 | -30,653 |
| Capital Expenditure | -785 | -617 | -371 | -263 | -1,890 |
| Free Cash Flow | -30,066 | -25,024 | -15,230 | -8,603 | -32,543 |